Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOSTER Evolving Study Platform
NCT07871864Phase 3Recruiting
- Sponsor
- Gustave Roussy
- Start
- Oct 2026
- Primary completion
- Jan 2035
- Countries
- 8
01
Overview
Phase 3, randomised trial in osteosarcoma (OS) comparing Cabozantinib with Best Supportive Care (2 arms). Primary endpoints: Event-Free Survival (Part 1) at 3 years and Event-Free Survival (Part 2) at 8 years. Started Oct 2026; status: recruiting.
02
Drugs
cabozantinib
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT07871864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07871864.